CTI BioPharma




MarketCap US

US United States


CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.


Founded in 1991, CTI BioPharma based in Seattle, Wash., is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers.

CTI BioPharma's mission is to develop targeted therapies that provide meaningful changes in patients' lives.

CTI BioPharma's vision is to become a leading provider of novel targeted therapies that meet the demands of healthcare providers and patients.

Key Team

Mr. James K. Fong (Exec. VP & Chief Commercial Officer)

Mr. Bruce K. Bennett Jr. (Sr. VP Global Pharmaceutical Operations)

Mr. John P. Volpone (Exec. VP & Chief of Staff)

Dr. Jennifer A. Smith (Sr. VP of Biometrics)

Recognition and Awards
CTI BioPharma has been recognized with a number of awards throughout its history, including the Washington Biotechnology & Biomedical Association's Pioneer of the Year award , the Fred Hutchinson Cancer Research Center's Visionary Award , and the American Cancer Society's Horizon Award .

CTI BioPharma
Leadership team

Dr. Adam R. Craig M.B.A., M.D., Ph.D. (Pres, CEO, Interim Chief Medical Officer & Director)

Mr. David H. Kirske (Exec. VP, CFO & Sec.)

Mr. Ed Bell (Sr. Director of Investor Relations)

Products/ Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Seattle, Washington, United States
Company Registration
SEC CIK number: 0000891293
20M - 100M
Traded as
Social Media
Fri Mar 01 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium